The peptide-based cancer treatments market is anticipated to grow from a valuation of US$ 10.1 billion in 2023 to US$ 21.4 billion by the end of 2033, expanding at a CAGR of 7.8%. For the manufacturer of the medicine bortezomib, expanding R&D efforts and ongoing clinical trials offer lucrative opportunities.
A peptide is a substance that results from the synthetic or organic chaining of amino acid monomers. Peptides have recently shown promise as therapeutic agents for the treatment of a number of illnesses, including cancer. The increasing potential of such cancer therapies is only expected to increase with new advancements in delivery, stability, alterations, and preclinical success.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=179?AS
Market Titans
- AstraZeneca
- Allergan plc
- Pfizer Inc.
- Abbott Laboratories
- AbbVie Inc.
- Johnson & Johnson
- Valeant Pharmaceuticals International Inc.
- Takeda Pharmaceutical Company Limited
Key Driving Forces Accelerating the Market Growth
- Among regions, North America is expected to remain the most attractive market for peptide based cancer therapeutics during the forecast period. This is largely due to the existence of several prominent peptide based cancer therapeutic drug makers and an advanced healthcare infrastructure in the region. Over the next couple of years, the region’s market is projected to witness a healthy growth. Meanwhile, the market in Asia-Pacific excluding Japan (APEJ) is anticipated to register the fastest CAGR over 2022.
- Based on drugs, demand for bortezomib is expected to remain relative higher as compared to other peptide based cancer therapeutic drugs. Revenues from global sales of bortezomib drugs currently commands for nearly 40% market share. Towards the end of 2022, more than US$ 4,700 Mn worth bortezomib drugs are estimated to be sold worldwide.
- Hospital pharmacies are the largest distribution channel for peptide based cancer therapeutic drugs followed by retail pharmacies. Currently, hospital pharmacies account for close to 50% share of the global market in terms of revenue. The trend is likely to continue in 2017 and beyond.
Competitive Strategies
To grow their market share, major companies are concentrating on product launches, quality assurance, mergers and acquisitions, pricing trends, and collaboration strategies. Businesses employ new product development and technological innovation as crucial tactics to expand their market share.
Leading companies participate in strategic alliances to improve product standards, meet safety rules, and lessen environmental effect. It is projected that market participants will have significant growth potential as a result of new peptide R&D.
Leading peptide therapy manufacturers are concentrating on expanding their markets through distribution agreements and market research into new markets. Established enterprises are now collaborating with local companies to increase their manufacturing capacity and improve their local presence.
For instance :
- In 2019, the Swiss pharmaceutical giant Novartis and the Japanese biotechnology company PeptiDream announced a new peptide drug conjugate (PDC) cooperation. To find novel macrocyclic and restricted peptides as PDCs against several targets of interest selected by Novartis, PeptiDream will leverage its own Discovery Platform System technology.
- In 2020, Sony Brook University (SBU) presented a cutting-edge method to treat advanced prostate cancer, which allowed SBU to prolong funding for FABP5 inhibitors through 2025. Researchers believe that the SBU-specific fatty acid binding protein (FABP) may aid in preventing cancer.
Industry Research
- By Drug Type :
- Goserelin
- Bortezomib
- leuprorelin
- Others
- By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Report Benefits & Key Questions Answered
- Peptide Based Cancer Therapeutics Category and segment level analysis:Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
- Peptide Based Cancer Therapeutics Historical volume analysis: The report provides a comparison of Peptide Based Cancer Therapeutics’s historical sales and projected sales performance for 2021-2031.
- Peptide Based Cancer Therapeutics Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Peptide Based Cancer Therapeutics market. It carefully gauges the impact of changing healthcare needs of key demographics globally
- Peptide Based Cancer Therapeutics Consumption by demographics: The report investigates consumer behavior affecting Peptide Based Cancer Therapeutics demand outlook for the assessment period. Effect of their keenness for digital trends on Peptide Based Cancer Therapeutics market is carefully analyzed
- Post COVID consumer spending on Peptide Based Cancer Therapeutics: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Peptide Based Cancer Therapeutics market growth.
Predominant Questions Answered in This Report Are:
- Which segments will perform well in the products and services market over the forecasted years?
- In which markets companies should authorize their presence.
- What are the forecasted growth rates for the products and services market?
- What are the long-lasting defects of the industry?
- How share market changes their values by different manufacturing brands?
- What are the qualities and shortcomings of the key players?
- What are the major end results and effects of the five strengths study of industry?
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=179?AS
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Email : [email protected]